GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Other Gross PPE

Daiichinkyo Co (TSE:4568) Other Gross PPE : 円498,517 Mil (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Other Gross PPE?

Daiichinkyo Co's Other Gross PPE for the quarter that ended in Mar. 2025 was 円498,517 Mil.

Daiichinkyo Co's quarterly Other Gross PPE increased from Sep. 2024 (円458,405 Mil) to Dec. 2024 (円487,470 Mil) and increased from Dec. 2024 (円487,470 Mil) to Mar. 2025 (円498,517 Mil).

Daiichinkyo Co's annual Other Gross PPE increased from Mar. 2023 (円348,912 Mil) to Mar. 2024 (円421,692 Mil) and increased from Mar. 2024 (円421,692 Mil) to Mar. 2025 (円498,517 Mil).


Daiichinkyo Co Other Gross PPE Historical Data

The historical data trend for Daiichinkyo Co's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Other Gross PPE Chart

Daiichinkyo Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 265,281.00 304,070.00 348,912.00 421,692.00 498,517.00

Daiichinkyo Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 421,692.00 - 458,405.00 487,470.00 498,517.00

Daiichinkyo Co Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Daiichinkyo Co Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

No Headlines